| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Shanghai Haohai Biological Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$42.35 |
| 52 Week High | HK$50.20 |
| 52 Week Low | HK$30.30 |
| Beta | 0.81 |
| 1 Month Change | 7.49% |
| 3 Month Change | 30.31% |
| 1 Year Change | 3.04% |
| 3 Year Change | -37.90% |
| 5 Year Change | n/a |
| Change since IPO | -31.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6826 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 3.4% | 8.1% | 2.8% |
| 1Y | 3.0% | -34.2% | -8.1% |
Return vs Industry: 6826 exceeded the Hong Kong Biotechs industry which returned -34.2% over the past year.
Return vs Market: 6826 exceeded the Hong Kong Market which returned -8.1% over the past year.
Price Volatility
| 6826 volatility | |
|---|---|
| 6826 Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in HK Market | 14.9% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 6826's share price has been volatile over the past 3 months.
Volatility Over Time: 6826's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 2,158 | Jianying Wu | www.3healthcare.com |
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. It offers ophthalmology products comprising intraocular lens, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, soft contact lens, medical sodium hyaluronate gels, injectors, scalpels, suture needles, and other products; orthopedics products, such as sodium hyaluronate injection and medical chitosan products; and anti-adhesion products, including medical sodium hyaluronate gel, and medical chitosan and collagen sponge products.
Shanghai Haohai Biological Technology Co., Ltd. Fundamentals Summary
| 6826 fundamental statistics | |
|---|---|
| Market cap | HK$15.53b |
| Earnings (TTM) | HK$466.98m |
| Revenue (TTM) | HK$2.88b |
15.2x
P/E Ratio2.5x
P/S RatioIs 6826 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6826 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.67b |
| Cost of Revenue | CN¥806.03m |
| Gross Profit | CN¥1.86b |
| Other Expenses | CN¥1.43b |
| Earnings | CN¥432.48m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.58 |
| Gross Margin | 69.81% |
| Net Profit Margin | 16.20% |
| Debt/Equity Ratio | 6.4% |
How did 6826 perform over the long term?
See historical performance and comparisonDividends
2.5%
Current Dividend Yield39%
Payout RatioDoes 6826 pay a reliable dividends?
See 6826 dividend history and benchmarks| Shanghai Haohai Biological Technology dividend dates | |
|---|---|
| Ex Dividend Date | Jun 06 2024 |
| Dividend Pay Date | Jul 19 2024 |
| Days until Ex dividend | 33 days |
| Days until Dividend pay date | 76 days |
Does 6826 pay a reliable dividends?
See 6826 dividend history and benchmarks